Memantine Glenmark (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, reducing excessive calcium influx caused by glutamate over‑activation. This moderates excitotoxic neuronal damage and supports synaptic function, which can translate into clinical benefits for Alzheimer’s patients.

The appropriate dose of Memantine Glenmark is determined by the prescribing clinician based on the patient’s age, disease severity, renal function and other individual factors. Dosage adjustments are made according to professional guidelines and patient response.

Safety data for memantine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Memantine Glenmark, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used for moderate to severe disease and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Memantine Glenmark should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Memantine Glenmark is taken orally, usually as a tablet. The tablet should be swallowed whole with water and can be taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious adverse events, although rare, include severe allergic reactions (rash, swelling, breathing difficulty), seizures, hallucinations or psychosis, and rapid heart rate. Patients should seek immediate medical attention if any of these symptoms occur.

Memantine Glenmark is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised in individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑antagonists without medical supervision.